The Innovative Drug Development Initiative (IDDI) of the Pulmonary Vascular Research Institute (PVRI): A series of four guidance documents for academics, drug regulators and industry partners.
作者信息
Corris Paul A, Nikkho Sylvia, Fernandes Peter
机构信息
Translational and Clinical Science Institute, Newcastle University, UK.
Bayer AG, Clinical Development, Berlin, Germany.
出版信息
Pulm Circ. 2020 Nov 18;10(4):2045894020963031. doi: 10.1177/2045894020963031. eCollection 2020 Oct-Dec.
Abstract
摘要
相似文献
1
The Innovative Drug Development Initiative (IDDI) of the Pulmonary Vascular Research Institute (PVRI): A series of four guidance documents for academics, drug regulators and industry partners.肺血管研究所（PVRI）的创新药物开发倡议（IDDI）：面向学术界、药品监管机构和行业合作伙伴的一系列四份指导文件。
Pulm Circ. 2020 Nov 18;10(4):2045894020963031. doi: 10.1177/2045894020963031. eCollection 2020 Oct-Dec.
2
Clinical trial design in phase 2 and 3 trials for pulmonary hypertension.肺动脉高压2期和3期试验的临床试验设计。
Pulm Circ. 2020 Jul 20;10(4):2045894020941491. doi: 10.1177/2045894020941491. eCollection 2020 Oct-Dec.
3
The IMI PROTECT project: purpose, organizational structure, and procedures.IMI 保护项目：目的、组织结构及程序。
Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:5-10. doi: 10.1002/pds.3933.
4
Cardiopulmonary bypass decreases pulmonary vascular resistance index after coronary artery bypass surgery.冠状动脉搭桥手术后，体外循环可降低肺血管阻力指数。
Scand J Clin Lab Invest. 2014 Jan;74(1):37-43. doi: 10.3109/00365513.2013.856032. Epub 2013 Nov 22.
5
Pulmonary vascular resistance index during coronary artery bypass surgery with aprotinin.
Scand J Clin Lab Invest. 2017 Sep;77(5):315-320. doi: 10.1080/00365513.2017.1318446. Epub 2017 May 2.
6
What is high risk? Redefining elevated pulmonary vascular resistance index in pediatric heart transplantation.什么是高危？重新定义儿科心脏移植中肺动脉阻力指数升高。
J Heart Lung Transplant. 2012 Jan;31(1):61-6. doi: 10.1016/j.healun.2011.08.021. Epub 2011 Oct 22.
7
Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure.影响吸入一氧化氮对急性呼吸衰竭心肺效应的因素。
Am J Respir Crit Care Med. 1995 Jul;152(1):318-28. doi: 10.1164/ajrccm.152.1.7599840.
8
Elevated pre-transplant pulmonary vascular resistance is not associated with mortality in children without congenital heart disease: a multicenter study.移植前肺血管阻力升高与无先天性心脏病儿童的死亡率无关：一项多中心研究。
J Heart Lung Transplant. 2015 Mar;34(3):448-56. doi: 10.1016/j.healun.2014.04.021. Epub 2014 May 9.
9
Pulmonary vascular resistance index: Getting the units right and why it matters.肺血管阻力指数：正确理解单位及其重要性
Clin Cardiol. 2019 Mar;42(3):334-338. doi: 10.1002/clc.23151. Epub 2019 Feb 27.
10
Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].充实被忽视疾病的研发渠道：创建一个以药物化学为核心的国际药物发现研究所[iDDi]。
Drug Discov Today. 2008 Feb;13(3-4):97-8. doi: 10.1016/j.drudis.2007.12.003. Epub 2008 Feb 1.
引用本文的文献
1
TRPC6, a therapeutic target for pulmonary hypertension.TRPC6 是肺动脉高压的治疗靶点。
Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1161-L1182. doi: 10.1152/ajplung.00159.2021. Epub 2021 Oct 27.
Zotero 插件